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Abstract
Background: Cadherins are essential components of the adherens junction complexes that mediate cell-cell adhesion and
regulate cell motility. During tissue morphogenesis, changes in cadherin expression (known as cadherin switching) are a
common mechanism for altering cell fate. Cadherin switching is also common during epithelial tumor progression, where it
is thought to promote tumor invasion and metastasis. E-cadherin is the predominant cadherin expressed in epithelial
tissues, but its expression is very limited in normal brain.
Methodology/Principal Findings: We identified E-cadherin expression in a retrospective series of glioblastomas exhibiting
epithelial or pseudoepithelial differentiation. Unlike in epithelial tissues, E-cadherin expression in gliomas correlated with an
unfavorable clinical outcome. Western blotting of two panels of human GBM cell lines propagated either as xenografts in
nude mice or grown under conventional cell culture conditions confirmed that E-cadherin expression is rare. However, a
small number of xenograft lines did express E-cadherin, its expression correlating with increased invasiveness when the cells
were implanted orthotopically in mouse brain. In the conventionally cultured SF767 glioma cell line, E-cadherin expression
was localized throughout the plasma membrane rather than being restricted to areas of cell-cell contact. ShRNA knockdown
of E-cadherin in these cells resulted in decreased proliferation and migration in vitro.
Conclusions/Significance: Our data shows an unexpected correlation between the abnormal expression of E-cadherin in a
subset of GBM tumor cells and the growth and migration of this aggressive brain tumor subtype.
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Introduction
Glioblastoma multiforme or glioblastoma (GBM) continues to
be the most frequently diagnosed and lethal of primary brain
tumors. This WHO grade IV brain tumor is remarkable in both its
morphological diversity and biologic aggressiveness, the latter
being partly due to its diffusely infiltrative nature [1,2]. Extensive,
diffuse parenchymal invasion is an important reason for failure of
the most accepted treatment modalities, including surgical
resection combined with radiation and chemotherapy. These
methods effectively target the main tumor and any remaining
tumor cells that are proliferating. However, non-proliferating
tumor cells are more resistant to cytotoxic therapies, and
migration away from the grossly detectable tumor mass can lead
to localized treatment failure beyond the surgical resection bed
and high-dose radiation zone [3].
Migrating cells undergo changes in cell-cell and cell-extracel-
lular matrix (ECM) adhesion that facilitate detachment from their
surroundings and promote motility. The transmembrane protein
family of cadherins regulates cell-cell adhesion during a variety of
biological processes, including tissue morphogenesis as well as
tumor invasion/metastasis [4–7]. Classical cadherins mediate cell-
cell adhesion and induce adhesion-related signaling via their
interaction with p120 catenin (p120) and b-catenin [8–10]. These
catenins, in turn, regulate a variety of processes, including
cadherin clustering and stabilization, modulation of Rho GTPase
signaling, actin cytoskeleton rearrangement, and gene transcrip-
tion [11,12]. Ultimately, such regulation governs the balance
between cell-cell adhesion on the one hand and cell motility on the
other, placing the cadherin-catenin complex in a significant
position to regulate both tumor cell proliferation and invasion.
Cadherins are critical players in an important mechanism that
underlies both developmental processes and epithelial tumorigen-
esis: the form of metaplasia known as epithelial-to-mesenchymal
transition (EMT). During EMT, the expression of the epithelial E-
cadherin is reduced in exchange for increased expression of
mesenchymal cadherins such as N-cadherin or cadherin-11 [13].
One result of this transition is cells that are more motile. A
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neural tube, allowing N-cadherin expressing cells in the developing
neuroepithelium to separate and migrate away from surrounding
E-cadherin expressing cells [14,15]. Further rounds of differential
cadherin expression are also thought to promote regionalization
during later stages of nervous system development [16,17]. The
classical cadherin superfamily (both Types I and II) consists of
more than 18 members, the differential expression of which occurs
at all stages of nervous system development and persists into
adulthood. Neurons that express a particular cadherin preferen-
tially form synapses with, and migrate into regions that express the
same cadherin [17,18]. Thus differential cadherin expression is a
general mechanism for regulating cell motility and promoting
brain regionalization. During epithelial tumor progression this
normal morphogenetic process is hijacked, and EMT is thought to
induce the invasion and metastasis of, among others, breast,
kidney, and colorectal cancer cells [6,15,19].
Previous examinations of cadherin expression in the normal
human adult nervous system indicate that E-cadherin expression is
rare, and limited to the arachnoid membrane [20–25]. In mice, E-
cadherin is also expressed in neural stem cells, where it regulates
self renewal [26]. On the other hand, mesenchymal cadherins such
as N-cadherin or cadherin 11 are expressed in multiple brain
regions, including the cortex and hippocampus, and are important
to normal nervous system function [18], with a possible role in
gliomagenesis or invasiveness. Only a handful of studies have
focused on the involvement of cadherins or catenins in high-grade
adult gliomas (anaplastic astrocytomas or GBMs) [22–25,27–29]
(reviewed in [30]). Most of these studies examined resected tumors
or glioblastoma cell lines and focused on the expression of E-
cadherin and N-cadherin protein. Consistently, E-cadherin
protein expression was found to be rare to non-existent in both
tumor and normal brain tissue [20,22,24,25,31], while N-cadherin
was extensively represented. In contrast to these results, two recent
studies argue that E-cadherin expression decreases with brain
tumor grade when compared to normal brain [27,32], raising the
possibility that a classic EMT is involved in glioma progression.
On balance, the existing data are inconclusive as to the
pathobiologic role of E-cadherin in high-grade adult gliomas.
We show here that E-cadherin expression is very limited in
normal brain, and rare in astrocytic and GBM tumors. Previously
we had examined the histopathologic, immunophenotypic, and
molecular characteristics of a rare form of GBM exhibiting
varying degrees of epithelial or pseudo-epithelial differentiation
[33]. In this study we found E-cadherin protein to be expressed in
one third of these tumors, and this expression correlated with
worse patient outcome. Therefore we sought to determine if the
expression of E-cadherin had functional consequences related to
tumor biology. Using multiple cell line models of GBM, it was
determined that expression of E-cadherin correlated with growth,
migration, and invasiveness. Taken together, our data suggest a
novel and potentially important role for E-cadherin in the lethality
of this subset of high-grade adult gliomas.
Results
E-cadherin expression is rare in GBM
We used immunohistochemistry to examine E-cadherin expres-
sion in brain tumor and non-neoplastic brain samples from three
tissue microarrays (TMAs): two constructed at the Mayo Clinic
containing a total of 83 glioblastoma (predominantly) or anaplastic
astrocytoma samples and one glioma invasion tissue microarray
containing 31 matched brain tumor rim/core samples (a generous
gift from M. Berens [34]). We initially probed the TMAs with the
clone 36 E-cadherin antibody, which is highly specific for E-
cadherin when used with Western Blot. However, in the context of
the formalin-fixed, paraffin-embedded samples of the TMAs, this
antibody produced non-specific staining (Figure S1), similar to
what has been reported previously [35]. Therefore the 4A2C7
antibody clone, which does not have this problem (Figure S1) was
used to evaluate E-cadherin expression. While E-cadherin staining
was clearly present in the infiltrating ductal breast carcinoma
samples on these TMAs, we did not find any E-cadherin
expression in any brain tumor or non-neoplastic brain sample
(data not shown). Thus brain- and brain tumor-associated E-
cadherin expression is rare.
E-cadherin expression in GBM with epithelial/
pseudoepithelial differentiation
We also performed immunohistochemistry to analyze E-
cadherin protein expression in tissue samples from 27 individual
cases with adequate clinical follow up of a rare sub-type of GBM
with epithelial/pseudoepithelial differentiation. These tumors
likely represent primary GBM based on a relatively short duration
of symptoms in patients with available history and lack of a
documented lower grade precursor per established criteria [36]. In
addition, molecular genetic changes typical of primary GBM were
present, including EGFR amplification (25%) or gain of chromo-
some 7 without amplification (50%), and whole chromosome 10
loss (57%). E-cadherin expression was present in 9 cases (33%).
The majority of the E-cadherin positive cases (8 out of 9 cases)
exhibited a restricted pattern of E-cadherin immunostaining, in
which E-cadherin was focally expressed in discrete nests of tumor
cells, usually reflecting areas of epithelial-like differentiation
(Figure 1A, Ai). In these positive cells, E-cadherin was expressed
primarily on the plasma membrane, but was dispersed, rather than
concentrated at areas of homotypic cell-cell contact as would be
expected (see [37] for an example of normal E-cadherin
distribution). In a single case (Figure 1B, Bi) E-cadherin expression
was more diffusely spread throughout most cells in the epithelial
component of the tumor. In this tumor, E-cadherin immunostain-
ing was both membranous and cytoplasmic. In contrast to E-
cadherin expression, b-catenin was present in all cases studied
(Figure 1C), with a membranous and cytoplasmic (56%) or
membranous only (44%) staining pattern. Patients whose tumors
expressed E-cadherin demonstrated poorer overall survival
compared to those that did not (Figure 1D; statistically significant
at p=0.021, log rank test). Although E-cadherin immunostaining
was more frequent in GBM with epithelial-like differentiation
(58%) compared with the adenoid (A-GBM) and epithelioid (E-
GBM) histologic subgroups (13%) [33], only E-cadherin expres-
sion was associated with survival. In contrast, there were no
significant associations between survival and age, tumor location,
tumor size, extent of resection, b-catenin immunostaining,
molecular cytogenetic abnormalities, or proliferative indices, nor
between E-cadherin immunostaining and any of those parameters
in this patient population (p.0.05).
E-cadherin expression in the GBM xenograft model
Because the expression of E-cadherin in normal central nervous
system tissue is rare and correlated with worse outcome for patients
with GBM, we used an experimental model of GBM to follow up
this observation. The Mayo GBM xenograft model is comprised of
19 primary GBM xenografts that were established directly from
patient tumor specimens and passaged exclusively in vivo as flank
xenografts. Orthotopic implantation of short-term explant cultures
derived from these xenograft lines results in tumors with
morphologic and genetic features similar to those seen in the
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ly recapitulates several key features of the human disease that are
lost in conventionally-cultured glioma cell lines, including retention
of markers such as EGFR overexpression and a tendency for the
orthotopically-implanted cells to invade throughout the mouse
brain [38–40]. Whole cell lysates were made from 19 of these tumor
lines using flank tumor specimens. These lysates were analyzed by
Western blot for the expression of various human cadherins and
catenins (Figure 2). All of the lines expressed b-catenin and p120
catenin, both important components of the cadherin/catenin cell-
cell adhesion signaling complex. Most of the lines expressed N-
cadherin and/or cadherin-11, which are frequently found in brain
tumors and normal brain. Surprisingly, 5 of the 19 lines examined
(GBMs 6, 8, 16, 26, and 34) expressed substantial amounts of E-
cadherin.The relative amountofE-cadherinproteinexpression was
low in the GBM xenograft lines compared to its expression in the E-
cadherin positive MCF7 breast cancer cell line, which was used in
this and later experiments as an example of a typical epithelial cell.
The difference in E-cadherin protein levels among these cell lines
was also reflected in E-cadherin mRNA levels (Lewis-Tuffin, data
not shown) andmay be dueto a focal ratherthan general expression
of E-cadherin in these tumors (similar to Figure 1A).
Eighteen of these xenograft lines were used to establish
orthotopic xenografts in mice, and mice were observed until
reaching a moribund state. The brains were then sectioned and
relative invasiveness was determined using H&E staining on up
to 10 mice per cell line. These xenograft lines were categorized
according to whether they were highly, moderately, minimally,
or non invasive (Figure S2). For subsequent analysis the highly
and moderately invasive lines were combined into one category
containing 8 lines (GBMs 6, 8, 15, 16, 26, 34, 38, and 44) and
the minimally and non invasive lines were combined into a
second category containing 10 lines (GBMs 5, 10, 12, 14, 22, 28,
36, 43, 46, and 59). The expression of E-cadherin in the
corresponding flank lysates was quantified relative to the amount
of actin protein in each lysate. This quantification was then
plotted versus the relative invasiveness of the xenograft lines in
mouse brain (Figure 3). Five of the eight highly/moderately
invasive lines expressed substantial amounts of E-cadherin
(GBMs 6, 8, 16, 26, 34) while none of the ten minimally/non-
invasive lines did. The data revealed that E-cadherin expression
was higher in the more invasive xenograft lines, suggesting that
E-cadherin expression and/or signaling may contribute to GBM
tumor aggressiveness.
Figure 1. E-cadherin expression correlates with worse outcome for patients with glioblastomas exhibiting epithelial appearance. A.
E-cadherin protein in 8 of the 9 positive cases was focally restricted to discrete nests of tumor cells, reflecting areas of epithelial-like differentiation. In
these positive cells E-cadherin was found primarily on the plasma membrane. However, unlike in normal epithelial cells, the localization of E-cadherin
was not concentrated at areas of homotypic cell-cell contact, but rather localized uniformly along the plasma membrane (indicated by arrows in Ai).
Left: Immunostain for E-cadherin (magnified in Ai to show detail); Right: H&E. The scale bar is 20 mm and applies to all Figure 1 images except Ai and
Bi. B. 1 of the 9 E-cadherin positive cases showed an unusually high expression of E-cadherin which was located both on the membrane and
cytoplasmically. Left: Immunostain for E-cadherin (magnified in Bi to show detail); Right: H&E of the tumor’s epithelial component. C. Two
independent examples of b-catenin localization by immunostain. Unlike E-cadherin, b-catenin is distributed throughout the tumor samples. D.
Individual cases of glioblastoma exhibiting epithelial or pseudoepithelial differentiation were analyzed by immunohistochemistry for the absence
(Negative) or presence (Membraneous/cytoplasmic) of E-cadherin protein. This data was correlated with overall survival using Kaplan-Meier analysis.
There is a statistically significant survival difference (p=0.021).
doi:10.1371/journal.pone.0013665.g001
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To further probe the role of E-cadherin in GBMs, we wanted to
apply standard cell biology techniques, including using interfering
RNA (RNAi) technology to knockdown E-cadherin expression.
Because conventionally cultured cell lines are more easily
manipulated, a panel of nineteen conventionally cultured glioma
cell lines was screened by Western blot for the presence of E-
cadherin, N-cadherin, cadherin-11, b-catenin, and p120 catenin
(Figure 4). As was seen with the xenograft cultured GBM lines, b-
catenin and p120 catenin were expressed in all lines and most lines
expressed N-cadherin and/or cadherin-11. Only the SF767 cell
line, derived from a recurrent anaplastic astrocytoma [41], was
found to express E-cadherin. Importantly, identical results were
obtained using the HECD1 anti-E-cadherin antibody (data not
shown). SF767 cells did not express either of the other two
cadherins evaluated. An original clone of the SF767 cell line was
independently obtained from the line’s original source (the UCSF/
Neurosurgery Tissue Bank) and showed an identical pattern of
cadherin expression (Lewis-Tuffin, data not shown). SF767 cells
co-segregate with several other GBM cell lines and primary GBM
tumors in gene expression studies [42]. Therefore, subsequent
experiments probing E-cadherin’s role were carried out in the
SF767 cell line under conventional culture conditions.
Role of E-cadherin in SF767 cell growth and motility
Initially, the localization of E-cadherin was assessed in SF767
cells using immunofluorescence (Figure 5). When grown under
conventional culture conditions, these cells exhibit a ‘‘spiky’’
appearance in which the cells are surrounded by filopodia. This
morphology is relatively common in mesenchymal cells but not in
cells that express functional, E-cadherin-based cell-cell adhesion
complexes, such as MCF7. The difference is particularly evident
when the organization of the actin cytoskeleton is examined
(Figure 5A). Actin protrusions into filopodia are evident on all sides
of the SF767 cells, including between adjacent cells at what should
be areas of cell-cell contact. This unusual morphology is in
contrast to the very tight areas of cell-cell contact exhibited by the
MCF7 cells, in which the actin cytoskeleton is organized in
junctional actin rings such that they cannot be distinguished from
each other in adjacent cells. Co-staining for E-cadherin in the
SF767 cells vs. the MCF7 cells revealed a similarly unusual
distribution. In MCF7 cells localization of E-cadherin was
restricted to the plasma membrane at areas of cell-cell contact
(Figure 5A,B). In SF767 cells E-cadherin was found across the
entire surface of the plasma membrane, as well as being distributed
in some cytoplasmic locations, particularly in peri-nuclear areas.
At areas of what should be cell-cell contact, E-cadherin staining
was diffuse and cells exhibited gaps and/or filopodia protrusions.
As a second means of examining areas of cell-cell contact,
SF767 and MCF7 cells were co-stained for E-cadherin and b-
catenin (Figure 5B). In MCF7 cells E-cadherin and b-catenin had
similar distributions to each other and were restricted primarily to
intercellular junctions. E-cadherin and b-catenin also co-localized
in SF767 cells. However their distribution was not restricted to
areas of cell-cell contact, with E-cadherin and b-catenin also found
Figure 2. E-cadherin protein expression occurs in a subset of xenograft glioma lines. Nineteen glioma cell lines propagated as xenografts
in mouse flank were examined by Western Blot for expression of various cadherin and catenin proteins. Actin serves as a loading control. Positive
control lysates are from MCF7 cells (E-cadherin, b-catenin), UMRC3 cells (N-cadherin), and MDA231 cells (cadherin-11). Low levels of E-cadherin
expression were detected in a small subset of these glioma xenografts.
doi:10.1371/journal.pone.0013665.g002
Figure 3. E-cadherin protein expression correlates with glioma
cell invasiveness in an orthotopic xenograft mouse model.
Xenograft cell lines 5, 6, 8, 10, 12, 14, 15, 16, 22, 26, 28, 34, 36, 38, 43, 44,
46, and 59 were examined for relative invasiveness following orthotopic
injection into mouse brain. Lines were categorized as highly,
moderately, minimally, or non invasive. The level of E-cadherin
expression (relative to actin expression) determined by Western blot
for each cell line was then plotted vs. relative glioma invasiveness. The
lines through the data indicate the median for each invasiveness
category; *indicates a statistical difference (one-tailed, unpaired t test)
between the two categories of invasiveness at p,0.05.
doi:10.1371/journal.pone.0013665.g003
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Even at cell-cell contact areas, many of the cells lacked tight
junctional staining, and exhibited gaps and/or filopodia protru-
sions (illustrated for example by the top arrow in Figure 5B). These
features, combined with the lack of actin re-organization,
suggested the absence of mature adherens junctions. The apparent
lack of mature adherens junctions in the SF767 cells raised the
question as to whether the E-cadherin expressed in these cells
might be mutated. Accordingly, E-cadherin mRNA was isolated
from these cells, converted to cDNA, and sequenced. No
mutations in the amino acid coding sequence were found
(Lewis-Tuffin, data not shown). Taken together, these observations
suggest that E-cadherin-mediated, cell contact-dependent signal-
ing may be deregulated in SF767 cells.
To begin to address the role of E-cadherin in SF767 growth and
migration, a lentiviral-based RNA knockdown approach was used.
Figure 4. E-cadherin expression in conventional glioma cell lines is rare. Nineteen conventionally grown glioma cell lines were examined by
Western Blot for expression of various cadherin and catenin proteins. a-tubulin serves as a loading control. Positive control lysates are as in Figure 2.
SF767 was the only conventional glioma cell line examined that expressed E-cadherin.
doi:10.1371/journal.pone.0013665.g004
Figure 5. SF767 cells lack junctional organization of actin and have disorganized adhesive structures containing E-cadherin. A.
Immunofluorescence for E-cadherin expression and actin localization was carried out on paraformaldehyde-fixed/Triton X-100-permeabilized SF767
and MCF7 cells (as a control). Arrows indicate areas of cell-cell contact; arrowheads point to areas of the plasma membrane without cell-cell contact.
MCF7 cells form compact cell-cell adhesions to which the actin cytoskeleton and E-cadherin tightly localize. In contrast, E-cadherin localization in
SF767 is at cell-cell contacts and on the plasma membrane at areas without cell-cell contact. Additionally, the actin cytoskeleton is not properly
organized at areas of cell-cell contact. 63X magnification. The scale bar is 10 mm and applies to all images in Figure 5. B. Immunofluorescence for E-
cadherin and b-catenin expression was carried out on MeOH-fixed/permeabilized SF767 and MCF7 cells. Arrows and arrowheads are as in A. b-catenin
and E-cadherin both localize tightly to adherens junctions between MCF7 cells. In contrast, fewer proper cell-cell junctions exist in the SF767 cells.
Both E-cadherin and b-catenin localization is diffusely distributed on the plasma membrane, in addition to a disorganized presence at areas of cell
contact. 63X magnification.
doi:10.1371/journal.pone.0013665.g005
E-Cadherin Expression in GBM
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target or one of five, non-overlapping, E-cadherin targeted
shRNAs. Two days later the cells were put into antibiotic selection
to produce a polyclonal population of cells with a stable
knockdown of E-cadherin. However, despite three attempts, the
few cell lines that survived selection contained E-cadherin protein
that was either not decreased or only partially affected (Lewis-
Tuffin and Huveldt, data not shown). To investigate the absence of
good E-cadherin knockdown, we repeated the six infections and
examined E-cadherin mRNA and protein levels at 2, 4, 7, and 10
days post infection (Figure 6A,B). The data suggest a direct
correlation between E-cadherin expression and SF767 cell growth
(Figure 6A, B). Cells infected with the shRNA that produced the
strongest depletion of endogenous E-cadherin (shEcad#21) died
off gradually but completely within 2 weeks post infection. Cells
infected with shRNAs that did not affect E-cadherin levels (non-
target shRNA, shEcad#20, or shEcad#22) were viable. Cells
infected with shRNAs that resulted in a partial E-cadherin
Figure 6. E-cadherin depletion inhibits SF767 growth and migration. A. SF767 cells were infected with lentivirus expressing either non-
target shRNA or E-cadherin shRNA on day zero, and then harvested on days 2, 4, 7, and 10 post-infection (p.i.). RNA from the cells was used for
quantitative RT-PCR analysis of CDH1 mRNA, normalized to the expression of GAPDH mRNA; data is plotted as fold change vs. the normalized CDH1
levels in wild-type SF767 cells. The shEcad#20 cell line was discarded after 7 days p.i. due to lack of difference with the pLKO-NT cells in terms of
growth rate, morphology, and CDH1 mRNA expression. The shEcad#21 cell line grew poorly and was completely harvested by 7 days p.i. B.
Additional cells were harvested on days 4, 7, and 10 p.i. for protein analysis. Western blot was used to determine knockdown of E-cadherin; a-tubulin
is a loading control. The generally poor condition of SF767-shEcad#21 cells by day 7 p.i. is reflected in the reduced levels of a-tubulin seen on the
blot, despite loading equal mg of total protein from each sample. C. Growth rates of E-cadherin-depleted SF767-shEcad#23 vs. control SF767-non
target cells were determined over 5 days using an MTT assay. E-cadherin-depleted SF767 cells grew more slowly than control SF767 cells. This
difference is statistically significant at 72, 96, and 120 hours in culture (2-way ANOVA followed by Bonferroni post hoc tests; * indicates p,0.05).
These two cell lines were generated independently of those displayed in parts A and B. D. Migration of E-cadherin-depleted SF767-shEcad#23 vs.
control SF767-non target cells (the same cell lines used for the growth experiment in C) was determined using a Boyden chamber trans-well
migration assay. Fewer E-cadherin-depleted SF767 cells than control SF767 cells migrated toward the chemoattractant. The difference is statistically
significant (paired t-test; * indicates p,0.05).
doi:10.1371/journal.pone.0013665.g006
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cadherin suppression over time (shEcad#24), or exhibited a
partial reduction of E-cadherin levels for the duration of these
studies (shEcad#23) (Figure 6A, B). Importantly, the shEcad#21
and shEcad#23 viruses were very effective (80–90% reduction) in
reducing endogenous E-cadherin expression in MCF7 cells,
without any evidence of a growth deficit in the cadherin-depleted
MCF7 cells (Figure S3). Taken together, these results strongly
suggest that SF767 cells are dependent on E-cadherin expression
for growth.
To follow up on this observation, we further examined the only
stable SF767 E-cadherin knockdown line that we obtained, which
was an incomplete knockdown produced by the shEcad#23
shRNA. Even this partial E-cadherin knockdown resulted in
SF767 cells that grew more slowly in culture than did their control,
non-target shRNA counterparts (Figure 6C). We also examined
the ability of these E-cadherin depleted cells to migrate towards a
gradient of FBS. To control for the growth effects of the E-
cadherin reduction, cells in this transwell assay were only allowed
to migrate for 6 hours. Figure 6D shows that the migration of E-
cadherin-reduced SF767 cells was significantly slower than that of
their non-target shRNA counterparts in this assay. Taken
together, these results indicate that E-cadherin plays a positive
role in the ability of the SF767 glioma cell line to grow and migrate
in vitro.
Discussion
E-cadherin is usually assigned a tumor suppressor role in
epithelial cells because it is lost in many carcinomas and its loss is
associated with a less favorable prognosis [43,44]. Loss of E-
cadherin in these tumors is associated with increased Ras, Rac1,
and MAPK signaling, which induce tumor cell growth and
invasion [45,46]. Conversely, re-expression of E-cadherin in such
tumor cells suppresses tumor cell growth and invasion [45,46].
However, under some circumstances, E-cadherin is associated
with increased tumorigenesis and tumor dispersion. Indeed, E-
cadherin expression, which is absent from the normal, mesenchy-
mally-derived ovary, is upregulated in the vast majority of
malignant ovarian tumors and correlates with increased survival,
proliferation, and metastatic spread of ovarian cancer cells [47,48].
Our data, presented here, are consistent with the idea that E-
cadherin expression is also an important component of tumor
growth and invasiveness in a rare subset of high-grade gliomas. We
have shown that, in patients with GBM exhibiting an epithelial/
pseudo-epithelial morphology, E-cadherin expression correlates
with a worse prognosis compared to patients that did not express
E-cadherin. E-cadherin expression also correlates with increased
invasiveness of glioma xenograft cell lines in an orthotopic mouse
model of invasion. Finally, endogenous E-cadherin expression
promotes the growth and migration of the conventional SF767
glioma cell line. Collectively, these results suggest an atypical role
for E-cadherin in brain glial tumor biology that, while uncommon,
may be of particular importance when it does occur. Our results
suggest that the cadherin class of cell adhesion molecules in
general, and E-cadherin in particular, may play a key role in the
biology of malignant gliomas.
The role and rarity of E-cadherin in gliomas contrasts with the
expression of E-cadherin in another type of nervous system tumor:
meningiomas. Meningiomas are derived from meningothelial/
arachnoid cells, which are some of the few normal nervous system
cells that do express E-cadherin. E-cadherin is expressed in most
meningiomas [21,22,49], and its loss may be associated with tumor
progression [20]. In contrast, in the case of GBM, epithelial
differentiation with E-cadherin expression is considered a
metaplastic (conversion) process in a glial tumor, similar to the
more commonly observed malignant mesenchymal component of
gliosarcomas. This interpretation is supported by the finding that
the glial and metaplastic components in either tumor type
(gliosarcoma or GBM) both exhibit similar genetic alterations
and apparently arise from a common precursor [33,50,51].
Our data on E-cadherin expression is consistent with the
majority of previous studies and shows that E-cadherin is not
expressed in normal brain, including neuronal cells, astrocytes,
oligodendrocytes, or the majority of GBMs. As 18 different
classical cadherins are thought to be expressed in brain, cadherin-
specific antibodies should be carefully screened for non-specific
effects, as indicated by our results with a widely used anti-E-
cadherin antibody (clone 36). The lack of E-cadherin expression in
normal brain also suggests that a classic EMT is not involved in
glioma progression. However, the process of EMT includes the
upregulation and downregulation of a variety of genes and
proteins, not just cadherins, which together cause the tumorigenic
transition [15,19]. The lack of classic epithelial-to-mesenchymal
cadherin-switching in ordinary glial tumorigenesis does not mean
that these other aspects of EMT are nonoperational. For example,
all of the E-cadherin positive GBMs with epithelial or pseudo-
epithelial differentiation were also positive for N-cadherin, a classic
EMT marker (Rodriguez, data not shown). In addition, many
conventional or serially transplanted GBM cell lines express
cadherin 11 (Figure 2, 4), another classic EMT marker.
Preliminary data suggest that cadherin 11 can promote GBM cell
growth and migration (Lewis-Tuffin, unpublished observations).
Indeed, a progression from a pro-neural to a mesenchymal
phenotype has been suggested by genomic studies in GBM tumors,
and is associated with poor prognosis [52].
E-cadherin expression in GBM appears to be an exception to
the EMT rule: when E-cadherin expression is turned on in these
tumors it is related to tumorigenesis and poor prognosis. The
molecular mechanisms underlying the contribution of E-cadherin
to growth and/or invasiveness in GBM are currently unknown.
Previous studies in epithelial tumor cells have shown that
mesenchymal cadherins (i.e. N-cadherin and cadherin 11) can
promote tumor cell growth and migration via p120-mediated
activation of Rac1 signaling [45,46]. Despite an initial activation
of Rac1 upon epithelial cell-cell contact, the overall level of Rac1
activity is normally suppressed by E-cadherin expression [45].
However, this E-cadherin effect is thought to be mediated by the
formation of mature cell-cell junctions [53,54]. In the SF767
glioma cell line, mature cell-cell junctions fail to form. It is
therefore possible that deregulated E-cadherin signaling causes
increased Rac1 activation and induces tumor cell growth and
invasion of human glioma cells.
Another possible mechanism by which E-cadherin could
regulate proliferation and parenchymal infiltration involves
adhesion-induced ligand-independent activation of the EGF
receptor, leading to Akt and MAPK activation. The occurrence
of such a mechanism has been demonstrated in the OVCAR-3
ovarian cancer cell line and is thought to underlie E-cadherin
effects in ovarian cancer in general [47]. This mechanism is
particularly intriguing to consider in the context of GBM, which is
known for the frequency with which it displays EGFR overex-
pression or expression of the constitutively-active EGFRvIII
mutant. It is of note that GBMs with epithelial and ‘‘adenoid’’
morphology show a decreased frequency of EGFR amplification
[33]. E-cadherin expression could represent an alternative
mechanism for activating the EGF pathway in this subset of
tumors.
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mechanics used by the invading tumor cells. Gliomas are known
for their diffusely infiltrative invasion pattern, in which the tumor
cells migrate as single cells. However the heterogeneity of glioma
genotypes, phenotypes, and surrounding tissue architecture
suggest that a diversity of migration mechanisms could be used,
even within the same tumor, at different stages of tumor dispersal.
Although E-cadherin expression in gliomas is rare, when it occurs
it could facilitate collective tumor cell migration strategies,
including migration as discrete cell clusters or as multicellular
strands or sheets, which are known to be dependent on cadherin
expression [55].
One question is whether the pro-tumorigenic function of E-
cadherin applies widely in gliomas or narrowly to GBM tumors
with pseudo-epithelial differentiation. Arguing for the latter,
ectopic overexpression of E-cadherin in the U87 glioma cell line
did not increase, but rather slightly decreased migration in vitro
(Lewis-Tuffin, unpublished observations). Unlike SF767 cells,
which only express E-cadherin, U87 cells also express endogenous
N-cadherin and cadherin-11, which could also affect migration-
and proliferation-related signaling. Therefore predicting the effect
of ectopic E-cadherin in GBM cell culture is not straightforward.
This will be an important issue to explore in future studies.
In conclusion, we have identified an unexpected association of
E-cadherin expression with aggressive biologic behavior in a rare
subset of GBM. The association of E-cadherin expression with
adverse clinical behavior should be interpreted with caution, given
the retrospective nature of the clinical/therapeutic data collected.
Nonetheless, both our clinical and pre-clinical data support the
conclusion that E-cadherin expression is associated with increased
aggressiveness in human GBM. These findings provide a glimpse
into the importance of the cadherin class of cell-cell adhesion
molecules in the biology of high grade astrocytic tumors. Future
studies should functionally dissect the specific molecular mecha-
nisms involving cadherins and associated proteins in glioma
biology. This will facilitate the identification of more reliable
prognostic biomarkers, and perhaps the development of novel
therapies.
Finally, our findings may also be relevant to epithelial tumor
biology. Despite the significance of EMT in epithelial tumor
progression and dissemination, many epithelial metastases retain
E-cadherin expression. The possibility that deregulated E-
cadherin function may promote the aggressiveness of these tumors
warrants further investigation.
Materials and Methods
Ethics Statement
All patient-related studies were approved by the Mayo Clinic
Institutional Review Board and therefore have been performed in
accordance with the ethical standards laid down in the Declaration
of Helsinki, including obtaining written informed consent prior to
donation of tissue. Animal studies were approved by the Mayo
Clinic Institutional Animal Care and Use Committee (IACUC
A5409) and were conducted according to Mayo Clinic IACUC
guidelines for animal husbandry.
GBM tissue microarray tumor specimens and
immunohistochemical analysis
Construction of the two Mayo Clinic human tissue microarrays
was performed as described in a previous publication [33]. Briefly,
83 cases of human high grade astrocytomas (11 cases of grade III
astrocytomas, 72 cases of GBMs) were used to construct two tissue
microarrays consisting of 3–4 0.6 cm diameter cores per tumor.
Each tissue microarray also contained samples of non-neoplastic
gray and white brain matter (obtained from epileptigenic brain),
infiltrating ductal carcinoma breast tissue, six GBM xenograft cell
lines, and U87 and U251 conventional glioma cell lines. The
human glioma rim-core tissue microarray was a gift from Michael
E. Berens (Translational Genomics Research Institute, Phoenix,
AZ) and has been described previously [34]. Immunohistochem-
istry for E-cadherin was performed on the three tissue microarrays
as described previously [33] using a monoclonal human anti E-
cadherin antibody (clone 4A2C7, Zymed/Invitrogen, Carlsbad,
CA).
Tumor specimens and immunohistochemical analyses of
GBMs with epithelial/pseudo-epithelial differentiation
Tumor classifications, tissue microarray construction, immuno-
histochemistry to analyze E-cadherin expression, and immunohis-
tochemical scoring were described in detail in a previous
publication [33]. Briefly: tumors from 32 patients from a
previously characterized retrospective series of glioblastomas with
varying degrees of epithelial morphology were stained with a
monoclonal human anti E-cadherin antibody (clone 4A2C7,
Zymed/Invitrogen, Carlsbad, CA) using tissue microarray sec-
tions. These tumors represent a rare subtype of GBM (,2%) and
were largely derived from pathology consultations. Clinical follow-
up was necessarily limited, but present in 27 patients (84%): 7
women and 20 men. The median age at diagnosis was 56 years
(interquartile range 44–67). The tumors were histologically
classified by previously published criteria as adenoid-GBM
(n=11), epithelioid GBM (n=4) or GBM with true epithelial
differentiation (n=12). Postoperative treatment approaches in-
cluded radiation therapy to the brain (50–60 Gy)(n=15), with
chemotherapy (n=6), including Temodar in 5 patients, or precise
treatment modality unknown (n=12). Immunohistochemical
scoring as either positive or negative was performed by a single,
blinded neuropathologist (F.J.R.). Univariate analyses of E-
cadherin immunoexpression with respect to overall and recur-
rence-free survival, as well as relevant clinicopathologic features
were performed using the log-rank test, and illustrated with
Kaplan Meier curves. All analyses were 2-sided with p-values
,0.05 considered statistically significant.
Xenograft information
Each of the 19 serially passaged xenograft cell lines used in this
study are derived from resected tumors from different human
patients and are propagated by serial transplantation in the flank
of nude mice [38]. Tumors are propagated exclusively in vivo in
order to preserve molecular and histopathologic features of the
primary patient tumor specimens. Eighteen of the xenograft cell
lines have been described previously [38,56–58]. GBM59 has not
been reported previously; the original tumor from which GBM59
was derived was also diagnosed as a GBM (Carlson and Sarkaria,
unpublished manuscript).
Orthotopic xenograft model and evalution of relative
invasiveness
Short-term explant cultures derived from flank tumor xeno-
grafts were injected orthotopically into nude mouse brain as
described previously [58]. Mice were euthanized when they
reached a moribund condition. Brains from these mice were
resected and then bisected along the needle tract used for injecting
the tumor cells. Half of each bisected brain was placed in formalin
and subsequently embedded in paraffin. These tissue samples were
processed for routine H&E staining in the TACMA Mayo core
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millimeters in the cerebral hemisphere ipsilateral to the injection,
up to a maximum diameter of approximately 6 mm in the
moribund state. The degree of invasiveness was evaluated on the
H&E sections by an observer (C.G.) who was blind to tumor E-
cadherin status. In tumors which were classified as ‘‘highly
invasive’’, tumor cells could be easily identified extending along
the commissural structures (corpus callosum and anterior
commissure) to the opposite hemisphere. In tumors which were
considered ‘‘minimally invasive’’ or ‘‘non invasive’’ a ‘‘nearly
sharp’’ border could be identified between the tumor mass and
surrounding brain parenchyma, with minimal or no intermixing of
tumor cells with surrounding parenchyma at the edge of the tumor
(Figure S2). A number of xenografts showed intermediate features
(‘‘moderate invasiveness’’) with cells extending well away from the
main tumor mass, but largely remaining in the ipsilateral
hemisphere.
Conventional cell culture
Established conventional cell lines were cultured on tissue-
culture treated plastic dishes at 37uC, 5% CO2, in DMEM media
containing 10% Fetal Bovine Serum (not heat-inactivated), an
additional 2 mM L-glutamine, and 1% non-essential amino acids.
Glioma cell lines include A172, CCF, D32, D37, H4, Hs683,
SW1088, SW1783, TP265, TP365, TP483, U87, U251, and
U373 (obtained from Bob Jenkins, Mayo Clinic, Rochester, MN);
G112P, SF767, T98G, and U118 (obtained from Joe Loftus, Mayo
Clinic, Scottsdale, AZ); LN229 (obtained from Wei Zhang, MD
Anderson Cancer Center, Houston, TX); and SF767 (obtained
from the UCSF/Neurosurgery Tissue Bank, San Francisco, CA).
MCF7, MDA-MB-231, and UMRC3 cell lines were also used.
Constructs
The MISSION Non-Target shRNA control vector pLKO-non
target (SHC002) and pLenti-human E-cadherin shRNA vectors,
both expressing a puromycin resistance gene, were purchased from
the Mission RNAi Consortium shRNA collection (Sigma-Aldrich,
St. Louis, MO) and obtained from the Mayo Clinic Comprehensive
Cancer Center RNA Interference Techonology Resource. E-
cadherin shRNA product numbers are: pLKO-shEcad#20,
TRCN0000039663; pLKO-shEcad#21, TRCN0000039664;
pLKO-shEcad#22, TRCN0000039665; pLKO-shEcad#23,
TRCN0000039666; pLKO-shEcad#24, TRCN0000039667.
Virus production and infections
Lentivirus stocks were produced using Virapower
TM lentivirus
packaging mix and the 293FT cell line according to the
manufacturer’s protocol (Invitrogen, Carlsbad, CA). SF767 cells
(obtained from J. Loftus) grown to 50% confluence were incubated
for 24 hours in a 1:1 dilution of virus:media with 4 mg/ml
Polybrene. After a 24-h recovery in complete media without virus,
polyclonal stable cell lines were selected and maintained in media
containing 5 mg/ml puromycin. In the parallel SF767 and MCF7
infection experiment, a 1:4 dilution of virus:media with 6 mg/ml
Polybrene was used.
Preparation of whole cell lysates for western blot
Flank xenograft tissue lysates: Flash frozen flank xenograft
tissues were homogenized at 0uC in SDS Lysis buffer (2% w/v
SDS, 4 M deionized urea, 62.5 mM Tris-Cl pH 6.8, 1 mM
EDTA, 5% v/v b-Mercaptoethanol, with 1 mM Na3VO4,5 0m M
NaF, and 1 mM PMSF). Lysates were then cleared by
centrifugation at 13000 rpm at 4uC for 20 minutes. Total protein
in the supernatents was quantified using the nitric acid method
[59], while the remaining lysates were mixed with Laemmli
Sample Buffer (2X final concentration, 0.1 M Tris-Cl pH 6.8, 2%
SDS, 10% sucrose, 0.24 M b-Mercaptoethanol, 0.008% bromo-
phenol blue) and boiled for 5 minutes before being analyzed by
Western Blot.
Conventional cell culture lysates: Whole cell lysates of
conventionally cultured cell lines were made by lysing the cells
in ice cold RIPA buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl,
1% Igepal CA-630 (NP-40 substitute), 0.5% Deoxycholic Acid,
0.1% SDS, with 1 mM Na3VO4, 1 mM EDTA, 50 mM NaF,
1 mM PMSF, 5 mg/ml leupeptin, and 2 mg/ml aprotinin) for 7
minutes, followed by brief sonication. Ten ml samples of each
lysate were quantitated for total protein using the BioRad Protein
Assay Dye Reagent (BioRad Laboratories, Hercules, CA).
Remaining lysates were mixed with Laemmli Sample Buffer (2X
final concentration) and boiled for 5 minutes before being
analyzed by Western Blot.
Western blotting
Equal mg amounts of protein lysates were separated by SDS-
PAGE and transferred to nitrocellulose filters using standard
methods. Blots were blocked in 5% nonfat dry milk in Tris-
buffered saline (TBS), pH 7.4 before being incubated in primary
antibodies in 5% milk/TBS. Blots were rinsed three times and
washed four times 5 minutes in TBS +0.1% Tween 20 (TBST).
Blots were then incubated with HRP-conjugated secondary
antibodies in 5% milk/TBS, and rinsed and washed in TBST as
before. Proteins were detected using Amersham ECL Western
Blotting Detection Reagents (GE Healthcare, Buckinghamshire,
United Kingdom). Primary antibodies were as follows: mouse anti-
p120 catenin (clone 15D2, Zymed/Invitrogen), rabbit anti-b
catenin (C2206, Sigma-Aldrich), mouse anti-E-cadherin (clone 36,
BD Biosciences, San Jose, CA), mouse anti-N-cadherin (clone 3B9,
Zymed/Invitrogen), mouse anti-cadherin-11 (clone 5B2H5,
Zymed/Invitrogen), rabbit anti-actin (A2066, Sigma-Aldrich),
and mouse anti-a-tubulin (clone B-5-1-2, T5168, Sigma-Aldrich).
HRP-conjugated secondary antibodies (anti-mouse and anti-
rabbit) were obtained from Jackson ImmunoResearch Laborato-
ries, West Grove, PA.
Immunofluorescence
SF767 and MCF7 cells were plated on glass coverslips and
allowed to adhere for a minimum of 24 hours. For combined E-
cadherin and actin analysis, cells were fixed with 3% paraformal-
dehyde at room temperature for 30 minutes, then washed twice in
PBS+10 mM glycine. Cells were permeabilized with PBS/0.2%
Triton X-100 for 2.5 minutes at room temperature, then washed
again with PBS/glycine before blocking and applying mouse anti-
E-cadherin primary antibody (clone 36, BD Biosciences). For
combined E-cadherin and b-catenin analysis, cells were fixed/
permeabilized by incubation in 100% methanol at 220uC for 7
minutes, then washed with PBS before blocking and applying
mouse anti-E-cadherin and rabbit anti-b catenin (C2206, Sigma-
Aldrich) primary antibodies. Secondary antibodies were goat anti
mouse Alexa 488 and goat anti rabbit Alexa 594 (Invitrogen).
Actin was localized by incubation with Alexa 594-conjugated
phalloidin (Invitrogen). SF767 and MCF7 cells were stained
simultaneously using identical conditions. Coverslips were mount-
ed on glass slides with Aqua Poly/Mount (Polysciences, Inc.
Warrington, PA). Cells were visualized with a Zeiss LSM 510
META laser scanning confocal microscope (Carl Zeiss Microima-
ging, Heidelberg, Germany) using a Plan-Apochromat 63x/1.4 oil
immersion objective. Images were acquired with the Zeiss AIM
E-Cadherin Expression in GBM
PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13665LSM510 software using a scan zoom of 1.7 and compiled in
Adobe Photoshop.
Quantitative RT-PCR analysis
Cells infected with non-target or shEcad-expressing viruses were
rinsed with 1xPBS. A portion of the cells on each plate were
scraped up using a cell lifter and transferred in PBS to a sterile
microfuge tube. The remaining cells were returned to culture
conditions for future sampling. For harvests in which both protein
and RNA were to be isolated, the cell sample was divided in half
prior to collecting the cells by centrifugation; the individual cell
pellets were then lysed for either RNA or protein isolation. Total
RNA was isolated using the miRCURY RNA Isolation Kit - Cell
and Plant (Exiqon Inc., Woburn, MA) according to manufacturer
protocol. Equal ng amounts of total RNA were converted to
cDNA using the High Capacity cDNA Reverse Transcriptase Kit
(Applied Biosystems Inc., Foster City, CA). qPCR reactions were
performed in triplicate with 10 ng of cDNA and TaqManH FAST
Universal PCR master mix (Applied Biosystems). Human CDH1
(ABI# Hs00170423_m1) and human GAPDH (ABI#
Hs99999905_m1) primer/probe sets were purchased from Ap-
plied Biosystems. All amplification data were collected with an
Applied Biosystems Prism 7900 sequence detector and analyzed
with Sequence Detection System software (Applied Biosystems).
Data were normalized to GAPDH, and mRNA abundance was
calculated using the DDCT method [60]. Samples with an average
GAPDH CT value greater than 1 CT (1 fold-change) away from the
wild-type GAPDH CT value were excluded from further analysis.
Boyden chamber migration assay
Migration assays were performed on 10 mm polycarbonate
membrane, 8 mm pore size, transwell culture inserts (upper
chamber) (Nalge Nunc International, Rochester, NY) coated with
15 mg/ml Bovine Type I collagen (BD Biosciences) and placed in
24 well plates (lower chamber). The day before the assay, culture
medium on the cells was changed to DMEM containing 250 mg/
ml BSA, with additional 2 mM L-glutamine and 1% non-essential
amino acids, and the cells incubated overnight at 37uC, 5% CO2.
The day of the assay, cells were harvested by a very brief
incubation in 0.25% Trypsin-EDTA, counted using Trypan Blue
exclusion to determine the number of live cells, and resuspended
in DMEM/BSA at 5610
5 cells/ml. 1610
5 cells were placed in the
upper chamber; DMEM/BSA containing 0.5% Fetal Bovine
Serum was placed in the lower chamber. Cells were allowed to
migrate to the underside of the transwell for 6 hours at 37uC, 5%
CO2. Any cells that remained in the upper chamber were removed
by gently scrubbing with cotton swabs. Cells on the underside of
the transwell chambers were collected by incubating the bottom of
the chamber in 225 ml of Cell Dissociation Buffer (equal parts
0.5% phenol red-free Trypsin EDTA (Invitrogen) and Hank’s
Balanced Salt Solution (5.37 mM KCl, 0.45 mM KH2PO4,
137 mM NaCl, 4.17 mM NaHCO3, 0.34 mM Na2HPO4,
5.55 mM D-glucose)) for 20 minutes at 37uC, 5% CO2. At the
end of this time 75 ml of a 4x Lysis+Dye Solution (20x Lysis
Solution and 400x GR DNA Binding Dye, both from the
CyQuant Cell Proliferation Assay kit (Invitrogen), diluted in water
to make a 4x stock solution) was added to the cell-containing
samples in the lower chamber under each transwell. Samples were
frozen at 280uC for at least 1 hour. They were then transferred to
a black, clear-bottom, 96-well plate and sample fluorescence read
by a SpectraMax M5 plate reader running SOFTmax PRO
software (Molecular Devices Corporation, Sunnyvale, CA) with
excitation at 480 nm and absorption at 520 nm. Sample
fluorescence for each cell type was normalized to the fluorescence
obtained from 0.25610
5 cells plated directly in triplicate wells of a
24 well plate, allowed to adhere for 6 hours at 37uC, 5% CO2, and
then quantified by the same method (incubation with Cell
Dissociation Buffer and 4x Lysis+Dye Solution followed by one
round of freeze-thaw lysis). This quantification method measures
DNA concentration to determine the relative number of cells in
each sample. Data were expressed as percentage of control (non-
target shRNA-transduced) cell migration and are presented as the
mean +/2 SEM of 4 independent experiments performed in
triplicate.
Cell growth assay
MTT cell growth assays were carried out by plating 4000 cells/
well in 96 well plates, with triplicate wells for each harvest. Cells
were allowed to grow for 24, 48, 72, 96, or 120 hours. Prior to
each harvest, cells were incubated with 1 mg/ml MTT (Sigma-
Aldrich) at 37uC, 5% CO2 for 1 hour. Formazan precipitate
(produced in proportion to the number of live cells) was then
extracted from the cells by replacing the media on the cells with
200 m/well DMSO (Sigma-Aldrich), pipetting up/down, and
incubating at 37uC, 5% CO2 for 5 minutes. The absorbance at
550 nm was then determined for each sample. Data were plotted
as mean +/2 SD. This experiment was performed three times in
triplicate; a representative plot is presented.
Statistics
Overall and recurrence-free survivals were evaluated using the
Kaplan-Meier method, performed with SAS software (SAS
Institute Inc., Cary, NC). Unpaired, one-tail t test (Figure 3),
two-way ANOVA and Bonferroni post hoc testing (Figure 6C),
and the paired t test (Figure 6D) were done using GraphPad Prism
4 software (GraphPad Software Inc., La Jolla, CA).
Supporting Information
Figure S1 Comparison of anti-human E-cadherin antibodies for
use with immunohistochemistry. Immunohistochemistry for E-
cadherin expression was carried out using either the 4A2C7
(Zymed/Invitrogen) or clone 36 (BD Transduction Labs) antibod-
ies on the Mayo Clinic GBM-A3 TMA. Among other samples, this
TMA includes non-neoplastic brain tissue (both gray and white
matter), a sample of infiltrating ductal carcinoma (IDC) breast
tumor, and a plug of U251 glioma cells. The scale bar is 20 mm
and applies to all images.
Found at: doi:10.1371/journal.pone.0013665.s001 (3.49 MB TIF)
Figure S2 Examples of minimally versus highly invasive
orthotopic GBM xenografts. H&E stain of mouse brain orthotop-
ically implanted with GBM xenograft line 12 (minimally invasive)
or GBM line 8 (highly invasive). Left images (12.5x magnification)
show a section of the entire brain; right images (200x) are
magnified to demonstrate the tumor/normal brain interface of the
two GBM lines. Left image scale bars are 1 mm; right image scale
bars are 50 mm.
Found at: doi:10.1371/journal.pone.0013665.s002 (4.05 MB TIF)
Figure S3 Comparison of E-cadherin shRNA effects on SF767
and MCF7 cells. A. SF767 cells were infected with freshly
prepared, high titer virus expressing non-target shRNA or
shEcad#21, #22, or #23. CDH1 mRNA levels in these cells
were quantified using qPCR at days 2, 4, and 6 post infection (p.i.;
top); E-cadherin protein expression was determined at days 4 and
6 p.i. using Western blot (bottom). The 6 day p.i. shEcad#21 and
4 and 6 day p.i. shEcad#23 samples are not shown because they
did not meet our qPCR normalization criteria. The generally poor
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levels of a-tubulin seen on the corresponding Western blots,
despite loading equal mg of total protein from each sample. B.
MCF7 cells were infected with the same freshly prepared, high
titer virus expressing non-target shRNA or shEcad#21, #22, or
#23. CDH1 mRNA levels in these cells were quantified using
qPCR at days 2, 4, 7, and 15 post infection (top); E-cadherin
protein expression was determined at days 4, 7, and 15 p.i. using
Western blot (bottom).
Found at: doi:10.1371/journal.pone.0013665.s003 (0.97 MB TIF)
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